Our locations are open for appointments and procedures. See how we're providing safe in-person care and telemedicine visits.

(Nuestras facilidades están abiertas para citas y procedimientos. Vea cómo brindamos atención segura en persona y visitas por medio de telemedicina.)
 

Learn More (Aprenda Más)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

view all Clinical Trials

Overview

The primary objectives are:

Phase 1

  • To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
  • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2 Phase 2
  • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2
  • To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status Phase 3
  • To evaluate and confirm the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status

Clinical Trial Information

Protocol

TIRB#: 27258

Phase

1/2

Condition(s)

Coronavirus (COVID-19)

Investigator

Gerard Criner, MD

Coordinator

N/A

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email breathe@tuhs.temple.edu or call 215-707-1359.

Full Title

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19